Provided by BIS Research
WHAT IS GERD?
Gastro-esophageal reflux disease or GERD is a chronic digestive disorder. It’s caused by a backflow of gastric contents into the esophagus due to weakened lower esophageal sphincter (LES). A major chunk of the present population suffers from GERD or its associated symptoms on a daily basis. In the U.S., 7% of its population are estimated to experience the main symptom, heartburn, daily.
The prevalence of GERD has increased by 50% over the last decade owing to the eventual change in the dietary patterns of the population. At present, the worldwide prevalence of GERD is around 15-25%. Not only does it affect an individual’s quality of life, but it also poses a threat of developing into esophageal cancer.
The GERD market is driven by the dearth of treatment options despite having options such as medication, devices or endoscopic procedures & surgery. The GERD market bifurcates into drugs and devices. Most of the prevalent and widely used drugs have gone off patent, and due to low safety, efficacy & poor reimbursement, devices and procedures are not popular among patients and physicians alike. The lack of new regulatory approved medication and lower acceptability of devices are some of the major limitations of the GERD market.
The onset of generics and OTC products have affected the growth of the GERD drugs market adversely. The lack of patent protected and new regulatory approved medicines have proved to be major reasons for the restrained growth of the drugs market. However, the market is dominated by drugs at present, as they are the first line treatment for early and mild cases of GERD. Although the market is well established in the drugs segment, there is a decline in the number of drugs in the pipeline.
According to a new market intelligence report by BIS Healthcare, titled ‘Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast (2017-2023)’, the global GERD drugs market is expected to account for $5.38 billion by 2023, with a nominal potential for growth in the future. However, the devices segment in the GERD market is exhibiting a strong growth potential owing to the side effects of drugs on long term use, patients who fail to respond to medication and the availability of new technology. The GERD devices market is expected to grow at a CAGR of 15.3% from 2017 to 2023.
The market intelligence report provides an in-depth analysis of the key development strategies and market trend dynamics which includes drivers, challenges and opportunities prevailing in the global GERD therapy market. The market has been divided into drugs and devices based on product type. The drugs segment, as an established market, offers antacids, Proton Pump Inhibitors (PPIs), H2RAs & prokinetics. Among these, PPIs hold the largest share of the market with 80% share, which is expected to be 75% by 2023. Moreover, the devices segment has been divided into invasive and non-invasive treatment procedures. Some of the prevalent devices in the market at present are MUSE, LINX reflux device, Stretta & GERD-X, etc.
This report also includes a separate segment on the profiles of major players in the market that allows the readers to get an insight into the various industry trends. Some of the leading companies in the market are:
- Takeda Pharmaceuticals Company Ltd.
- Johnson & Johnson
- Endogastric Solutions
Stay up-to-date with the latest trending news stories and industry advances with the Research and Markets blog. Don’t forget to connect with us on LinkedIn and Twitter for the latest blog plus information about new products.